SCHEMBL21495079

SCHEMBL21495079

COc1ccc(CN(C(=O)O)c2nc(-c3cccc(N4CCOCC4)n3)cs2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
MEN1 O00255 7/20 0.42
KMT2A Q03164 7/20 0.42
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
NPSR1 Q6W5P4 3/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CETP P11597 1/20 0.40
WNT3A P56704 1/20 0.40
GSTO1 P78417 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21505830 0.90 MAPT (0.45) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL21495067 0.88 MAPT (0.51) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL24170725 0.78 MAPT (0.47) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL21495080 0.77 MAPT (0.46) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL21505889 0.76 LMNA (0.46) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL21484608 0.72 MAPT (0.44) MAPTLMNARAB9ANPC1MEN1
SCHEMBL21484702 0.71 KMT2A (0.46) MAPTLMNARAB9ANPC1MEN1
SCHEMBL16211589 0.69 GSTO1 (0.54) MAPTLMNAMAPK1RAB9AMEN1
SCHEMBL21495058 0.68 MEN1 (0.38) MAPTLMNAMAPK1RAB9ANPC1
SCHEMBL29194779 0.68 MAPT (0.48) MAPTLMNAMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MAPT 706/4885LMNA 522/4885MAPK1 3578/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MAPT 706/4885LMNA 522/4885MAPK1 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.